

**You're invited to join us for an interactive discussion on**  
**Simplifying Topical Treatment in Dermatology:**  
**ZORYVE Across Three Major Inflammatory Dermatoses –**  
**Atopic Dermatitis,**  
**Seborrheic Dermatitis, and Plaque Psoriasis**

**Thursday, November 6, 2025**  
**6:00 PM Central Time**

**Ko Fusion**  
**30 E Main Street**  
**Champaign, IL 61820**

**Janet Cook at 217-649-9794**

**Presented by**



Jennifer Conner, MPAS, PA-C  
Physician Assistant  
Dawes Fretzin Dermatology Group  
Westfield, IN

**Please RSVP at**

**RSVP**

**or call 217.649.9794**

## **INDICATIONS**

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

## IMPORTANT SAFETY INFORMATION

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

**Flammability:** The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions ( $\geq 1\%$ ) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions ( $\geq 1\%$ ) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions ( $\geq 1\%$ ) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%). The most common adverse reactions ( $\geq 1\%$ ) for ZORYVE foam 0.3% for plaque psoriasis include headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

The most common adverse reactions ( $\geq 1\%$ ) for ZORYVE foam 0.3% for plaque psoriasis include headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

Please see full [Prescribing Information](#) for ZORYVE cream and full [Prescribing Information](#) for ZORYVE foam.

This event is being offered for US healthcare professionals only. No spouses, family, or other guests are permitted to attend. All attendance at Kowa-sponsored events is documented and may be disclosed as required by state or federal law.

Kowa acknowledges that certain employers and institutions may have restrictions pertaining to participation in industry-sponsored activities. You are accountable for understanding and complying with those restrictions that pertain to you. Thank you for your understanding and compliance.

If you no longer want to receive emails from KOWA Pharmaceuticals, please [opt out](#)  
[Privacy Policy | Kowa Holdings America, Inc.](#)

Kowa Pharmaceuticals America, Inc.  
530 Industrial Park Blvd., Montgomery, AL 36117